The short version of cold chain fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-18. Anything still debated is marked as such rather than presented as settled.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Reconstitution solvent depends on peptide solubility and intended use; water, buffer, or small amounts of organic solvent may be needed. After dissolution, solutions are typically aliquoted into single-use portions to avoid repeated freeze-thaw cycles. Aliquots are stored at -20 °C or -80 °C, depending on stability. Labels include concentration, solvent, date, and operator. Sterile filtration may be used when microbial control is required, but filters can adsorb peptides. The optimal concentration and solvent are often determined empirically.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
| Property | Value | Notes |
|---|---|---|
| Form | Lyophilized powder or frozen solution | Powder is generally more stable for long-term storage. |
| Recommended storage | -20 °C, desiccated, protected from light | -80 °C for solutions or sensitive sequences. |
| Reconstitution solvent | Water, buffer, or organic co-solvent | Choice depends on peptide solubility and assay. |
| Freeze-thaw stability | Limited; avoid repeated cycles | Aliquoting into single-use portions reduces damage. |
| Contamination control | Aseptic technique and sterile filtration | Filters may adsorb peptides; validate recovery. |
Practical handling begins with an inventory record that links each vial to a lot number, synthesis date, and purity certificate. Before opening a container, allow it to equilibrate to room temperature to prevent condensation on the powder. Weighing or transferring should occur in a low-humidity environment using tools that minimize static and adsorption. Hygroscopic peptides may gain water quickly, changing mass and concentration estimates. Recording the container's initial mass and any visible changes supports later reconciliation of material.
Reconstitution introduces additional variables: solvent choice, pH, ionic strength, and filtration. Many sequences dissolve readily in water, while hydrophobic ones may need acetonitrile, dimethyl sulfoxide, or a small amount of base. Adding solvent slowly and avoiding vigorous vortexing can reduce foaming and shear-induced aggregation. If the solution appears cloudy, filtration may remove particulates but can also remove aggregated peptide and alter concentration. A clear solution does not by itself confirm correct sequence or purity, so analytical checks remain necessary.
Temperature logs and cold-chain documentation help identify excursions that may compromise a batch. Automated freezers, desiccant packs, and sealed containers limit moisture and frost accumulation. Aliquoting small portions before freezing reduces the number of times the main stock changes temperature. Labels should include peptide name, lot, concentration if known, solvent, and date prepared. Periodic analytical verification by high-performance liquid chromatography or mass spectrometry can detect degradation, truncation, or sequence errors that visual inspection cannot reveal.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
=== Subdivision === Viola is a large genus that has traditionally been treated in sections. One of these was that of Gingins (1823), based on stigma morphology, with five sections (Nomimium, Dischidium, Chamaemelanium, Melanium, Leptidium). The extensive taxonomic studies of Wilhelm Becker, culminating in his 1925 conspectus, resulted in 14 sections and many infrasectional groups. The largest and most diverse, being section Viola, with 17 subsections. In addition to subsections, series were also described. Alternatively, some authors have preferred to subdivide the genus into subgenera. Subsequent treatments were by Gershoy (1934) and Clausen (1964), using subsections and series. These were all based on morphological characteristics. Subsequent studies using molecular phylogenetic methods, such as that of Ballard et al. (1998) have shown that many of these traditional divisions are not monophyletic, the problem being related to a high degree of hybridization. In particular section Nomimium was dismembered into several new sections and transferring part of it to section Viola. Section Viola s. lat. is represented by four sections, Viola sensu stricto, Plagiostigma s. str., Nosphinium sensu lato. and the V. spathulata group. In that analysis, the S American sections appear to be the basal groups, starting with Rubellium, then Leptidium. However, the exact phylogenetic relationships remain unresolved, as a consequence many different taxonomic nomenclatures are in use, including groupings referred to as Grex. Marcussen et al.
==== Sequencing by expansion ==== On February 2025, Roche announced development of a new, proprietary sequencing method relying on small molecules. This method "encode[s] the sequence of a target nucleic acid molecule (DNA or RNA) into a measurable surrogate polymer called an Xpandomer", and combined amplification with later detected by a nanopore platform with a CMOS camera.
there is an alphabet of single characters, each denoting a specific amino acid or a set of amino acids; a string of characters drawn from the alphabet denotes a sequence of the corresponding amino acids; any string of characters drawn from the alphabet enclosed in square brackets matches any one of the corresponding amino acids; e.g. [abc] matches any of the amino acids represented by a or b or c. The fundamental idea behind all these notations is the matching principle, which assigns a meaning to a sequence of elements of the pattern notation:
=== Opposition front bencher: 1967–70 === In 1967, Peter Walker invited Heseltine to be opposition spokesman on transport (not a Shadow Cabinet-level position, but reporting to Walker), after he had arranged a successful speaking tour of the West Country for him. Heseltine's duties included opposing Barbara Castle's 1967 Transport Bill (which eventually became the Transport Act 1968). Heseltine led opposition to the parts of the bill which nationalised small bus companies into the National Bus Company (UK) and set up Passenger transport executives (PTEs) in major urban areas. He criticised Castle for wanting to give PTEs the right to manufacture or produce anything necessary for their function, which as she pointed out was almost word-for-word identical to a clause in the Conservatives' Transport Act 1962. In 1968 Margaret Thatcher became Heseltine's boss for a year; he found her "embarrassingly rude". Unusually for the time, he employed a full-time researcher, Eileen Strathnaver. Heath allowed his shadow ministers more leeway than would be normal nowadays. Heseltine was one of a group of 15 Conservative MPs to vote against the 1968 Commonwealth Immigration Bill on second reading (Conservative whips advised their MPs to support it, but it was a free vote). He also voted against the bill on three subsequent votes, arguing that it was based on "sheer naked racialism" and that Britain should honour promises previously made to the Kenyan Asians.
Sources: en.wikipedia.org
== Portrayal in the media == Woodroof’s life was the basis of the 2013 film Dallas Buyers Club. He was portrayed in the film by Matthew McConaughey, who won an Academy Award for Best Actor for his performance as Woodroof.
Florey was full of praise for their achievement, but disturbed that they had turned to the Americans for advice instead of him. "Am I not Australian?" he asked Keogh, "Have I not had some leading role in this thing?"
The Asilomar Conference on Recombinant DNA was an influential conference organized by Paul Berg, Maxine Singer, and colleagues to discuss the potential biohazards and regulation of biotechnology, held in February 1975 at a conference center at Asilomar State Beach, California. A group of about 140 professionals (primarily biologists, but also including lawyers and physicians) participated in the conference to draw up voluntary guidelines to ensure the safety of recombinant DNA technology. The conference also placed scientific research more into the public domain, and can be seen as applying a version of the precautionary principle. The effects of these guidelines are still being felt through the biotechnology industry and the participation of the general public in scientific discourse. Due to potential safety hazards, scientists worldwide had halted experiments using recombinant DNA technology, which entailed combining DNAs from different organisms. After the establishment of the guidelines during the conference, scientists continued with their research, which increased fundamental knowledge about biology and the public's interest in biomedical research.
Sources: en.wikipedia.org
No. Allowing the sealed vial to equilibrate to room temperature reduces condensation on the powder. Condensation can introduce moisture and promote degradation. Equilibration usually takes 15 to 30 minutes depending on vial size.
Aliquoting limits repeated freeze-thaw cycles that can cause aggregation or loss. Single-use portions reduce contamination risk and handling variability. It also allows separate testing without disturbing the main stock.
Inspect packaging, temperature indicators, and vial condition before storage. Record any deviations from the expected temperature range. If a deviation occurred, analytical testing may be warranted before use.
Allow the sealed vial to equilibrate to room temperature so condensation does not form on the powder or solution. Wipe the exterior with a suitable disinfectant if the workspace requires it. Open the vial in a clean, draft-free area to reduce contamination.